| Literature DB >> 22621278 |
Salik Hussain1, Stijn Smulders, Vanessa De Vooght, Bert Ectors, Sonja Boland, Francelyne Marano, Kirsten L Van Landuyt, Benoit Nemery, Peter H M Hoet, Jeroen A J Vanoirbeek.
Abstract
We determined the ability of a model nanoparticle (NP) (titanium dioxide, TiO(2)) to modulate sensitization induced by a known potent dermal sensitizer (dinitrochlorobenzene) using a variant of the local lymph node assay called lymph node proliferation assay.BALB/c mice received sub-cutaneous injections of vehicle (2.5 mM sodium citrate), TiO(2) NPs (0.004, 0.04 or 0.4 mg/ml) or pigment particles (0.04 mg/ml) both stabilized in sodium citrate buffer at the base of each ear (2x50μl), before receiving dermal applications (on both ears) of 2,4-Dinitrochlorobenzene (DNCB) (2x25μl of 0.1%) or its vehicle (acetone olive oil - AOO (4:1)) on days 0, 1 and 2. On day 5, the stimulation index (SI) was calculated as a ratio of (3)HTdR incorporation in lymphocytes from DNBC-treated mice and AOO-treated controls. In a second experiment the EC(3)-value for DNCB (0 to 0.1%) was assessed in the absence or presence of 0.04 mg/ml TiO(2). In a third experiment, the lymphocyte subpopulations and the cytokine secretion profile were analyzed after TiO(2) (0.04 mg/ml) and DNCB (0.1%) treatment. Injection of NPs in AOO-treated control mice did not have any effect on lymph node (LN) proliferation. DNCB sensitization resulted in LN proliferation, which was further increased by injection of TiO(2) NPs before DNCB sensitization. The EC(3) of DNCB, with prior injection of vehicle control was 0.041%, while injection with TiO(2) decreased the EC(3) of DNCB to 0.015%. TiO(2) NPs pre-treatment did not alter the lymphocyte subpopulations, but significantly increased the level of IL-4 and decreased IL-10 production in DNCB treated animals.In conclusion, our study demonstrates that administration of nano-TiO(2) increases the dermal sensitization potency of DNCB, by augmenting a Th(2) response, showing the immunomodulatory abilities of NPs.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22621278 PMCID: PMC3583227 DOI: 10.1186/1743-8977-9-15
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Figure 1Physico-chemical characteristics of TiO nano (A) and pigment (B) particles in powder and suspension.
Figure 2Effect of subcutaneous injections of TiONPs or pigment particles on the skin sensitizing capacity of 0.1% DNCB. Stimulation Index in lymph node proliferation assay (LNPA). To calculate the SI, all SI’s of the AOO-treated were pooled, since they were not statistically different from each other. Graph shows mean ± SD, n = 5–9, * p < 0.05 and ** p < 0.01.
Figure 3Effect of subcutaneous injections of 0.04 mg/mlTiONPs on the dose–response curve (SI) of DNCB sensitization. Mice were exposed to different doses of DNCB in the presence or absence of TiO2 NP pre-treatment (0.04 mg/ml). The EC3 value of Veh/DNCB is 0.041% (⇢), while the EC3 of TiO2/DNCB is 0.015% (→). Graph shows mean ± SD, n = 5-9, *p < 0.05.
Lymph node cell subpopulations (x10 ) per lymph node
| 0.66 ± 0.21 | 2.06 ± 0.56*** | 1.16 ± 0.57 | 2.27 ± 0.59+++ | |
| 0.47 ± 0.15 | 1.47 ± 0.41*** | 0.81 ± 0.38 | 1.56 ± 0.43+++ | |
| 0.04 ± 0.01 | 0.16 ± 0.05*** | 0.06 ± 0.03 | 0.13 ± 0.02++ | |
| 0.18 ± 0.06 | 0.59 ± 0.15*** | 0.34 ± 0.20 | 0.68 ± 0.19+++ | |
| 0.12 ± 0.04 | 0.62 ± 0.22*** | 0.23 ± 0.13 | 0.80 ± 0.30+++ |
Results are expressed as mean ± SD, n = 9-11, ***p < 0.001 Veh/DNCB vs Veh/AOOand ++p < 0.01, +++p < 0.001 TiO2/DNCB vs. TiO2/AOO.
Figure 4Lymphocyte cytokine production after 0.1% DNCB dermal sensitization or AOO treatment with prior injection of 0.04 mg/ml TiO2 or vehicle. On day 5, the auricular lymph nodes are removed and lymphocytes are cultured for 42 h in the presence of ConA. Cytokines are determined in LNC supernatant. Graphs show mean ± SD, n = 10–12, *p < 0.05, ** p < 0.01 and *** p < 0.001.